1	CONTROLLED SUBSTANCE AMENDMENTS
2	2013 GENERAL SESSION
3	STATE OF UTAH
4	Chief Sponsor: Evan J. Vickers
5	House Sponsor: Paul Ray
6 7	LONG TITLE
8	General Description:
9	This bill amends provisions of the Utah Controlled Substances Act regarding Schedule
10	V controlled substances and unscheduled controlled substances.
11	Highlighted Provisions:
12	This bill:
13	 adds all forms of tramadol to the list of Schedule V controlled substances; and
14	 adds new "spice" and "bath salts" analogs to the list of unscheduled controlled
15	substances.
16	Money Appropriated in this Bill:
17	None
18	Other Special Clauses:
19	None
20	Utah Code Sections Affected:
21	AMENDS:
22	58-37-4, as last amended by Laws of Utah 2012, Chapter 297
23	58-37-4.2 , as last amended by Laws of Utah 2012, Chapter 297
24	
25	Be it enacted by the Legislature of the state of Utah:
26	Section 1. Section 58-37-4 is amended to read:
27	58-37-4. Schedules of controlled substances Schedules I through V Findings



28	required Specific substances included in schedules.
29	(1) There are established five schedules of controlled substances known as Schedules l
30	II, III, IV, and V which consist of substances listed in this section.
31	(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by
32	the official name, common or usual name, chemical name, or brand name designated:
33	(a) Schedule I:
34	(i) Unless specifically excepted or unless listed in another schedule, any of the
35	following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
36	ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
37	chemical designation:
38	(A) Acetyl-alpha-methylfentanyl(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-
39	N-phenylacetamide);
40	(B) Acetylmethadol;
41	(C) Allylprodine;
42	(D) Alphacetylmethadol, except levo-alphacetylmethadol also known as
43	levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
44	(E) Alphameprodine;
45	(F) Alphamethadol;
46	(G) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
47	propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
48	(H) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
49	piperidinyl]-N-phenylpropanamide);
50	(I) Benzylpiperazine;
51	(J) Benzethidine;
52	(K) Betacetylmethadol;
53	(L) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
54	piperidinyl]-N-phenylpropanamide);
55	(M) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
56	phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
57	(N) Betameprodine;
58	(O) Betamethadol;

59	(P) Betaprodine;
60	(Q) Clonitazene;
61	(R) Dextromoramide;
62	(S) Diampromide;
63	(T) Diethylthiambutene;
64	(U) Difenoxin;
65	(V) Dimenoxadol;
66	(W) Dimepheptanol;
67	(X) Dimethylthiambutene;
68	(Y) Dioxaphetyl butyrate;
69	(Z) Dipipanone;
70	(AA) Ethylmethylthiambutene;
71	(BB) Etonitazene;
72	(CC) Etoxeridine;
73	(DD) Furethidine;
74	(EE) Hydroxypethidine;
75	(FF) Ketobemidone;
76	(GG) Levomoramide;
77	(HH) Levophenacylmorphan;
78	(II) Morpheridine;
79	(JJ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
80	(KK) Noracymethadol;
81	(LL) Norlevorphanol;
82	(MM) Normethadone;
83	(NN) Norpipanone;
84	(OO) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
85	propanamide;
86	(PP) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
87	(QQ) Phenadoxone;
88	(RR) Phenampromide;
89	(SS) Phenomorphan;

90	(TT) Phenoperidine;
91	(UU) Piritramide;
92	(VV) Proheptazine;
93	(WW) Properidine;
94	(XX) Propiram;
95	(YY) Racemoramide;
96	(ZZ) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
97	(AAA) Tilidine;
98	(BBB) Trimeperidine;
99	(CCC) 3-methylfentanyl, including the optical and geometric isomers
100	(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and
101	(DDD) 3-methylthiofentanyl
102	(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide).
103	(ii) Unless specifically excepted or unless listed in another schedule, any of the
104	following opium derivatives, their salts, isomers, and salts of isomers when the existence of the
105	salts, isomers, and salts of isomers is possible within the specific chemical designation:
106	(A) Acetorphine;
107	(B) Acetyldihydrocodeine;
108	(C) Benzylmorphine;
109	(D) Codeine methylbromide;
110	(E) Codeine-N-Oxide;
111	(F) Cyprenorphine;
112	(G) Desomorphine;
113	(H) Dihydromorphine;
114	(I) Drotebanol;
115	(J) Etorphine (except hydrochloride salt);
116	(K) Heroin;
117	(L) Hydromorphinol;
118	(M) Methyldesorphine;
119	(N) Methylhydromorphine;
120	(O) Morphine methylbromide;

121	(P) Morphine methylsulfonate;
122	(Q) Morphine-N-Oxide;
123	(R) Myrophine;
124	(S) Nicocodeine;
125	(T) Nicomorphine;
126	(U) Normorphine;
127	(V) Pholcodine; and
128	(W) Thebacon.
129	(iii) Unless specifically excepted or unless listed in another schedule, any material,
130	compound, mixture, or preparation which contains any quantity of the following hallucinogenic
131	substances, or which contains any of their salts, isomers, and salts of isomers when the
132	existence of the salts, isomers, and salts of isomers is possible within the specific chemical
133	designation; as used in this Subsection (2)(iii) only, "isomer" includes the optical, position, and
134	geometric isomers:
135	(A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
136	α -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α -ET; and AET;
137	(B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
138	4-bromo-2,5-dimethoxy-α-methylphenethylamine; 4-bromo-2,5-DMA;
139	(C) 4-bromo-2,5-dimethoxypenethylamine, some trade or other names:
140	2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
141	(D) 2,5-dimethoxyamphetamine, some trade or other names:
142	2,5-dimethoxy-α-methylphenethylamine; 2,5-DMA;
143	(E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
144	(F) 4-methoxyamphetamine, some trade or other names:
145	4-methoxy-α-methylphenethylamine; paramethoxyamphetamine, PMA;
146	(G) 5-methoxy-3,4-methylenedioxyamphetamine;
147	(H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
148	4-methyl-2,5-dimethoxy-α-methylphenethylamine; "DOM"; and "STP";
149	(I) 3,4-methylenedioxy amphetamine;
150	(J) 3,4-methylenedioxymethamphetamine (MDMA);
151	(K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-

152	alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
153	(L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
154	N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
155	(M) 3,4,5-trimethoxy amphetamine;
156	(N) Bufotenine, some trade and other names:
157	3-(β-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,
158	N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
159	(O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
160	(P) Dimethyltryptamine, some trade or other names: DMT;
161	(Q) Ibogaine, some trade and other names:
162	7-Ethyl-6,6β,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
163	[5,4-b] indole; Tabernanthe iboga;
164	(R) Lysergic acid diethylamide;
165	(S) Marijuana;
166	(T) Mescaline;
167	(U) Parahexyl, some trade or other names:
168	3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
169	(V) Peyote, meaning all parts of the plant presently classified botanically as
170	Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from
171	any part of such plant, and every compound, manufacture, salts, derivative, mixture, or
172	preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
173	(W) N-ethyl-3-piperidyl benzilate;
174	(X) N-methyl-3-piperidyl benzilate;
175	(Y) Psilocybin;
176	(Z) Psilocyn;
177	(AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis
178	(cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis
179	plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives,
180	and their isomers with similar chemical structure and pharmacological activity to those
181	substances contained in the plant, such as the following: $\Delta 1$ cis or trans tetrahydrocannabinol,
182	and their optical isomers $\Delta 6$ cis or trans tetrahydrocannabinol, and their optical isomers $\Delta 3,4$

183 cis or trans tetrahydrocannabinol, and its optical isomers, and since nomenclature of these 184 substances is not internationally standardized, compounds of these structures, regardless of 185 numerical designation of atomic positions covered; 186 (BB) Ethylamine analog of phencyclidine, some trade or other names: 187 N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine, 188 N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE; 189 (CC) Pyrrolidine analog of phencyclidine, some trade or other names: 190 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP; 191 (DD) Thiophene analog of phencyclidine, some trade or other names: 192 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and 193 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy. 194 (iv) Unless specifically excepted or unless listed in another schedule, any material 195 compound, mixture, or preparation which contains any quantity of the following substances 196 having a depressant effect on the central nervous system, including its salts, isomers, and salts 197 of isomers when the existence of the salts, isomers, and salts of isomers is possible within the 198 specific chemical designation: 199 (A) Mecloqualone; and 200 (B) Methaqualone. 201 (v) Any material, compound, mixture, or preparation containing any quantity of the 202 following substances having a stimulant effect on the central nervous system, including their 203 salts, isomers, and salts of isomers: 204 (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 205 4,5-dihydro-5-phenyl-2-oxazolamine; 206 (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone, 207 alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone; 208 (C) Fenethylline; 209 (D) Methcathinone, some other names: 2-(methylamino)-propiophenone; 210 alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; 211 alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone; 212 methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of

213

optical isomers;

214	(E) (±)cis-4-methylaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
215	(F) N-ethylamphetamine; and
216	(G) N,N-dimethylamphetamine, also known as
217	N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
218	(vi) Any material, compound, mixture, or preparation which contains any quantity of
219	the following substances, including their optical isomers, salts, and salts of isomers, subject to
220	temporary emergency scheduling:
221	(A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
222	(B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
223	(vii) Unless specifically excepted or unless listed in another schedule, any material,
224	compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate
225	(gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
226	(b) Schedule II:
227	(i) Unless specifically excepted or unless listed in another schedule, any of the
228	following substances whether produced directly or indirectly by extraction from substances of
229	vegetable origin, or independently by means of chemical synthesis, or by a combination of
230	extraction and chemical synthesis:
231	(A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
232	opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone
233	and their respective salts, but including:
234	(I) Raw opium;
235	(II) Opium extracts;
236	(III) Opium fluid;
237	(IV) Powdered opium;
238	(V) Granulated opium;
239	(VI) Tincture of opium;
240	(VII) Codeine;
241	(VIII) Ethylmorphine;
242	(IX) Etorphine hydrochloride;
243	(X) Hydrocodone;
244	(XI) Hydromorphone;

245	(XII) Metopon;
246	(XIII) Morphine;
247	(XIV) Oxycodone;
248	(XV) Oxymorphone; and
249	(XVI) Thebaine;
250	(B) Any salt, compound, derivative, or preparation which is chemically equivalent or
251	identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these
252	substances may not include the isoquinoline alkaloids of opium;
253	(C) Opium poppy and poppy straw;
254	(D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
255	any salt, compound, derivative, or preparation which is chemically equivalent or identical with
256	any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives,
257	and salts of isomers and derivatives, whether derived from the coca plant or synthetically
258	produced, except the substances may not include decocainized coca leaves or extraction of coca
259	leaves, which extractions do not contain cocaine or ecgonine; and
260	(E) Concentrate of poppy straw, which means the crude extract of poppy straw in either
261	liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.
262	(ii) Unless specifically excepted or unless listed in another schedule, any of the
263	following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
264	ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
265	chemical designation, except dextrorphan and levopropoxyphene:
266	(A) Alfentanil;
267	(B) Alphaprodine;
268	(C) Anileridine;
269	(D) Bezitramide;
270	(E) Bulk dextropropoxyphene (nondosage forms);
271	(F) Carfentanil;
272	(G) Dihydrocodeine;
273	(H) Diphenoxylate;
274	(I) Fentanyl;
275	(J) Isomethadone;

276	(K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol,
277	levomethadyl acetate, or LAAM;
278	(L) Levomethorphan;
279	(M) Levorphanol;
280	(N) Metazocine;
281	(O) Methadone;
282	(P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
283	(Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic
284	acid;
285	(R) Pethidine (meperidine);
286	(S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
287	(T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
288	(U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
289	(V) Phenazocine;
290	(W) Piminodine;
291	(X) Racemethorphan;
292	(Y) Racemorphan;
293	(Z) Remifentanil; and
294	(AA) Sufentanil.
295	(iii) Unless specifically excepted or unless listed in another schedule, any material,
296	compound, mixture, or preparation which contains any quantity of the following substances
297	having a stimulant effect on the central nervous system:
298	(A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
299	(B) Methamphetamine, its salts, isomers, and salts of its isomers;
300	(C) Phenmetrazine and its salts; and
301	(D) Methylphenidate.
302	(iv) Unless specifically excepted or unless listed in another schedule, any material,
303	compound, mixture, or preparation which contains any quantity of the following substances
304	having a depressant effect on the central nervous system, including its salts, isomers, and salts
305	of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
306	specific chemical designation:

307	(A) Amobarbital;
308	(B) Glutethimide;
309	(C) Pentobarbital;
310	(D) Phencyclidine;
311	(E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
312	1-piperidinocyclohexanecarbonitrile (PCC); and
313	(F) Secobarbital.
314	(v) (A) Unless specifically excepted or unless listed in another schedule, any material,
315	compound, mixture, or preparation which contains any quantity of Phenylacetone.
316	(B) Some of these substances may be known by trade or other names:
317	phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
318	(vi) Nabilone, another name for nabilone:
319	(±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
320	6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
321	(c) Schedule III:
322	(i) Unless specifically excepted or unless listed in another schedule, any material,
323	compound, mixture, or preparation which contains any quantity of the following substances
324	having a stimulant effect on the central nervous system, including its salts, isomers whether
325	optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers,
326	and salts of isomers is possible within the specific chemical designation:
327	(A) Those compounds, mixtures, or preparations in dosage unit form containing any
328	stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were
329	listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the
330	Code of Federal Regulations, and any other drug of the quantitive composition shown in that
331	list for those drugs or which is the same except that it contains a lesser quantity of controlled
332	substances;
333	(B) Benzphetamine;
334	(C) Chlorphentermine;
335	(D) Clortermine; and
336	(E) Phendimetrazine.
337	(ii) Unless specifically excepted or unless listed in another schedule, any material,

338	compound, mixture, or preparation which contains any quantity of the following substances
339	having a depressant effect on the central nervous system:
340	(A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
341	pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients
342	which are not listed in any schedule;
343	(B) Any suppository dosage form containing amobarbital, secobarbital, or
344	pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug
345	Administration for marketing only as a suppository;
346	(C) Any substance which contains any quantity of a derivative of barbituric acid or any
347	salt of any of them;
348	(D) Chlorhexadol;
349	(E) Buprenorphine;
350	(F) Any drug product containing gamma hydroxybutyric acid, including its salts,
351	isomers, and salts of isomers, for which an application is approved under the federal Food,
352	Drug, and Cosmetic Act, Section 505;
353	(G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine:
354	± -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
355	(H) Lysergic acid;
356	(I) Lysergic acid amide;
357	(J) Methyprylon;
358	(K) Sulfondiethylmethane;
359	(L) Sulfonethylmethane;
360	(M) Sulfonmethane; and
361	(N) Tiletamine and zolazepam or any of their salts, some trade or other names for a
362	tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:
363	2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:
364	4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,
365	flupyrazapon.
366	(iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
367	U.S. Food and Drug Administration approved drug product, some other names for dronabinol:
368	(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or

369 (-)-delta-9-(trans)-tetrahydrocannabinol.

(iv) Nalorphine.

- (v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:
- (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
- (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;
- (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;
- (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;
- (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;
- (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;
- (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts; and
- (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, non-narcotic ingredients in recognized therapeutic amounts.
- (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids including any of the following or any isomer, ester, salt, or derivative of the following that promotes muscle growth:

400	(A) Boldenone;
401	(B) Chlorotestosterone (4-chlortestosterone);
402	(C) Clostebol;
403	(D) Dehydrochlormethyltestosterone;
404	(E) Dihydrotestosterone (4-dihydrotestosterone);
405	(F) Drostanolone;
406	(G) Ethylestrenol;
407	(H) Fluoxymesterone;
408	(I) Formebulone (formebolone);
409	(J) Mesterolone;
410	(K) Methandienone;
411	(L) Methandranone;
412	(M) Methandriol;
413	(N) Methandrostenolone;
414	(O) Methenolone;
415	(P) Methyltestosterone;
416	(Q) Mibolerone;
417	(R) Nandrolone;
418	(S) Norethandrolone;
419	(T) Oxandrolone;
420	(U) Oxymesterone;
421	(V) Oxymetholone;
422	(W) Stanolone;
423	(X) Stanozolol;
424	(Y) Testolactone;
425	(Z) Testosterone; and
426	(AA) Trenbolone.
427	(vii) Anabolic steroids expressly intended for administration through implants to cattle
428	or other nonhuman species, and approved by the Secretary of Health and Human Services for
429	use, may not be classified as a controlled substance.
430	(d) Schedule IV:

431 (i) Unless specifically excepted or unless listed in another schedule, any material, 432 compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not 433 less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them. 434 (ii) Unless specifically excepted or unless listed in another schedule, any material, 435 compound, mixture, or preparation which contains any quantity of the following substances, 436 including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and 437 salts of isomers is possible within the specific chemical designation: 438 (A) Alprazolam; 439 (B) Barbital; 440 (C) Bromazepam; 441 (D) Butorphanol; 442 (E) Camazepam; 443 (F) Carisoprodol; 444 (G) Chloral betaine; 445 (H) Chloral hydrate; 446 (I) Chlordiazepoxide; 447 (J) Clobazam; 448 (K) Clonazepam; 449 (L) Clorazepate; 450 (M) Clotiazepam; 451 (N) Cloxazolam; 452 (O) Delorazepam; 453 (P) Diazepam; 454 (Q) Dichloralphenazone; 455 (R) Estazolam; 456 (S) Ethchlorvynol; 457 (T) Ethinamate; 458 (U) Ethyl loflazepate; 459 (V) Fludiazepam; 460 (W) Flunitrazepam; 461 (X) Flurazepam;

```
462
             (Y) Halazepam;
463
             (Z) Haloxazolam;
464
             (AA) Ketazolam;
465
             (BB) Loprazolam;
466
             (CC) Lorazepam;
467
             (DD) Lormetazepam;
468
             (EE) Mebutamate;
469
             (FF) Medazepam;
470
             (GG) Meprobamate;
471
             (HH) Methohexital;
472
             (II) Methylphenobarbital (mephobarbital);
473
             (JJ) Midazolam;
474
             (KK) Nimetazepam;
             (LL) Nitrazepam;
475
476
             (MM) Nordiazepam;
477
             (NN) Oxazepam;
478
             (OO) Oxazolam;
479
             (PP) Paraldehyde;
480
             (QQ) Pentazocine;
481
             (RR) Petrichloral;
482
             (SS) Phenobarbital;
483
             (TT) Pinazepam;
484
             (UU) Prazepam;
485
             (VV) Quazepam;
486
             (WW) Temazepam;
487
             (XX) Tetrazepam;
488
             (YY) Triazolam;
489
             (ZZ) Zaleplon; and
490
             (AAA) Zolpidem.
491
             (iii) Any material, compound, mixture, or preparation of fenfluramine which contains
492
      any quantity of the following substances, including its salts, isomers whether optical, position,
```

or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible.

- (iv) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric isomers, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:
- 500 (A) Cathine ((+)-norpseudoephedrine);
- 501 (B) Diethylpropion;
- 502 (C) Fencamfamine;
- 503 (D) Fenproprex;
- 504 (E) Mazindol;

493

494

495

496497

498

499

515

516

517

518

519

520

- 505 (F) Mefenorex;
- 506 (G) Modafinil;
- 507 (H) Pemoline, including organometallic complexes and chelates thereof;
- 508 (I) Phentermine;
- 509 (J) Pipradrol;
- 510 (K) Sibutramine; and
- 511 (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
- 512 (v) Unless specifically excepted or unless listed in another schedule, any material, 513 compound, mixture, or preparation which contains any quantity of dextropropoxyphene 514 (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
 - (e) Schedule V: Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
 - (i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
- 521 (ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 522 grams;
- 523 (iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100

524	grams;
525	(iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of
526	atropine sulfate per dosage unit;
527	(v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
528	(vi) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
529	atropine sulfate per dosage unit; [and]
530	(vii) unless specifically exempted or excluded or unless listed in another schedule, any
531	material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant
532	effect on the central nervous system, including its salts, isomers, and salts of isomers[-]; and
533	(viii) all forms of Tramadol.
534	Section 2. Section 58-37-4.2 is amended to read:
535	58-37-4.2. Listed controlled substances.
536	The following substances, their analogs, homologs, and synthetic equivalents are listed
537	controlled substances:
538	(1) AM-694; 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone;
539	(2) AM-2201; 1-(5-fluoropentyl)-3-(1-naphthoyl)indole;
540	(3) CP 47,497 and its C6, C8, and C9 homologs; 2-[(1R,3S)-3-hydroxycyclohexyl]
541	-5-(2-methyloctan-2-yl)phenol;
542	(4) Ethylphenidate;
543	[(4)] <u>(5)</u> Fluoromethcathinone;
544	[(5)] <u>(6)</u> HU-210; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
545	-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
546	[(6)] (7) HU-211; Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
547	methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
548	[(7)] (8) JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone;
549	[(8)] (9) JWH-018; Naphthalen-1-yl-(pentylindol-3-yl)methanone {also known as
550	1-Pentyl-3-(1-naphthoyl)indole};
551	[(9)] <u>(10)</u> JWH-019; 1-hexyl-3-(1-naphthoyl)indole;
552	[(10)] (11) JWH-073; Naphthalen-1-yl(1-butylindol-3-yl)methanone {also known as
553	1-Butyl-3-(1-naphthoyl)indole};
554	[(11)] (12) JWH-081; 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone;

555	[(12)] (13) JWH-122; CAS#619294-47-2; (1-Pentyl-3-(4-methyl-1-naphthoyl)indole);
556	[(13)] (14) JWH-200; 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
557	[(14)] (15) JWH-203; 1-pentyl-3-(2-chlorophenylacetyl)indole;
558	[(15)] (16) JWH-210; 4-ethyl-1-naphthalenyl(1-pentyl-1H-indol-3-yl)-methanone;
559	[(16)] (17) JWH-250; 1-pentyl-3-(2-methoxyphenylacetyl)indole;
560	[(17)] (18) JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone;
561	[(18)] (19) JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
562	[(19)] (20) RCS-4; 1-pentyl-3-(4-methoxybenzoyl)indole;
563	[(20)] (21) RCS-8; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole {also
564	known as BTW-8 and SR-18};
565	[(21)] (22) 4-methylmethcathinone {also known as mephedrone};
566	[(22)] (23) 3,4-methylenedioxypyrovalerone {also known as MDPV};
567	[(23)] (24) 3,4-Methylenedioxymethcathinone {also known as methylone}; [and]
568	[(24)] <u>(25)</u> 4-methoxymethcathinone[-];
569	(26) 5F-AKB48; 1-(5-flouropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-
570	<u>carboxamide;</u>
571	(27) 25B-NBOMe; 2-(r-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
572	methyl]ethanamine; and
573	(28) 25C-NBOMe; 2-(4Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
574	methyl]ethanamine.

Legislative Review Note as of 3-1-13 7:56 AM

Office of Legislative Research and General Counsel